Aridis pharmaceuticals announces 2021 fourth quarter and year-end financial results and business update

Awarded funding from the gates foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and covid-19 los gatos, calif. , march 31, 2022 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended december 31, 2021.
ARDS Ratings Summary
ARDS Quant Ranking